Cagrilintide (10 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Cagrilintide is a long-acting, acylated analogue of the pancreatic hormone amylin, studied as a once-weekly agent for appetite regulation. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed in the published research record, not a recommendation for use in humans or animals.

For a 10 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of about 3.33 mg/mL (3,333 mcg/mL). At that concentration, every 0.10 mL drawn on a U-100 insulin syringe equals 10 units and delivers roughly 0.333 mg of material, so a 0.6 mg step lands near 18 units and the 4.5 mg maintenance step near 135 units.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow dose-escalation pattern used in the Phase 2 dose-finding work, where the weekly amount was stepped up roughly every two weeks to manage gastrointestinal tolerability before settling at a maintenance level.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (3.33 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Supplies Needed

• Cagrilintide vials (10 mg): ~2 vials for an 8-week run; ~4 vials for a 12-week run; ~6 vials for a 16-week run at the maintenance dose.
• Insulin syringes (U-100, 1 mL): 8 for an 8-week schedule, 12 for 12 weeks, 16 for 16 weeks (one fresh syringe per draw; maintenance volume may need two draws).
• Bacteriostatic water (10 mL): one bottle covers a short run; two bottles for a 12–16 week schedule.
• Alcohol swabs: roughly 16 for 8 weeks, 24 for 12 weeks, 32 for 16 weeks — a single 100-count box covers any of these.

Protocol Overview

• Research goal: model appetite and body-weight regulation via central amylin-receptor agonism.
• Schedule: once-weekly subcutaneous administration in the published model.
• Dose band: 0.6 mg starting step up to a 4.5 mg weekly maintenance level.
• Fill: 10 mg lyophilized, reconstituted to 3.33 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the 0.6 mg step and hold each level for about two weeks before escalating.
• Keep administration on a fixed weekly cadence and the same day where possible for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• The 4.5 mg maintenance step carried the strongest efficacy signal in the dose-finding data.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light and moisture, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about 30 days. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Split larger volumes — the 4.5 mg step exceeds a single 1 mL syringe — across two draws.
• Document each draw — date, volume, remaining material — for reproducibility.

How Cagrilintide Works

Cagrilintide is a synthetic, lipid-modified analogue of amylin, a hormone co-secreted with insulin from pancreatic beta cells. It acts on central amylin receptors — concentrated in the area postrema and surrounding hindbrain — to dampen appetite and reduce energy intake. The acylation extends its circulating half-life to roughly 160–195 hours, which is what supports a once-weekly dosing cadence. Because amylin signalling is mechanistically distinct from the incretin (GLP-1/GIP) pathway, Cagrilintide is studied both on its own and paired with a GLP-1 agonist in the comparative literature.

Reported Benefits & Side Effects

Benefits observed in trials

• About 10.8% average body-weight reduction over 26 weeks at the 4.5 mg weekly dose, versus roughly 3.0% on placebo in the Phase 2 study.
• A clear dose-dependent response, with the 2.4–4.5 mg steps showing the largest effect.
• When combined with semaglutide 2.4 mg in the CagriSema program, Phase 3 work reported roughly 20% weight reduction at 68 weeks.
• Once-weekly exposure sufficient to support sustained appetite suppression across the dosing interval.

Side effects reported

• Predominantly gastrointestinal — nausea, vomiting, diarrhoea and constipation — most common during escalation.
• Generally mild-to-moderate and transient, and reduced by slower titration.
• Occasional mild redness or irritation at subcutaneous injection sites.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, balanced nutrition reflected in the published study designs.
• Combined resistance and aerobic activity to preserve lean mass during weight reduction.
• Seven to nine hours of sleep, stress management, hydration and electrolyte monitoring as standard trial controls.

Injection Technique (Reference Only)

• Wipe the vial stopper and the site with alcohol swabs and let them dry.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily, then hold for about 5–10 seconds before withdrawing.
• Split volume across sites when it exceeds a comfortable single injection, rotate sites weekly (abdomen, thighs, upper arms), and dispose of sharps in an approved container.

References

Related Protocols